Evidence map›Paper›PMID 21316923›Full record

ReviewSchizophrenia research2011

Schizophrenia, "Just the Facts" 6. Moving ahead with the schizophrenia concept: from the elephant to the mouse.

Matcheri S Keshavan, Henry A Nasrallah, Rajiv Tandon

Abstract readReview
In one paragraph

Review in Schizophrenia research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. What's in the name "schizophrenia"? A clinical, research and lived experience perspective.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2023
    Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Observational
  16. Neuroimaging in Schizophrenia.Neuroimaging clinics of North America · 2020
    Review
  17. Review
  18. Article
  19. Article
  20. Renaming schizophrenia: 5 × 5.Epidemiology and psychiatric sciences · 2019
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Matcheri S KeshavanDepartment of Psychiatry, Beth Israel Deaconess Medical Center and Massachusetts Mental Health Center, Harvard Medical School, Boston, MA 02215, USA. mkeshava@bidmc.harvard.edu
Henry A Nasrallah
Rajiv Tandon

Funding

WITHIN SUBJ VARIABILITY IN MEASUREMENTS DRUG METABOL ENZYMES IN HLTY SUBJM01RR000056 · NCRR · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LEVINE, ARTHUR S · 1985 to 2006
$29.2M
Stability of Biotypes: a Longitudinal EvaluationR01MH078113 · NIMH · WAYNE STATE UNIVERSITY · PI KESHAVAN, MATCHERI S. · 2007 to 2019
$6.2M
Brain Maturation and Vulnerability to SchizophreniaR01MH064023 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KESHAVAN, MATCHERI S. · 2003 to 2008
$3.0M
CORTICAL PRUNING AND SCHIZOPHRENIAK02MH001180 · NIMH · WAYNE STATE UNIVERSITY · PI KESHAVAN, MATCHERI S. · 1995 to 2005
$648k
NCRR NIH HHS M01 RR000056NIMH NIH HHS K02 MH001180NIMH NIH HHS MH64023NIMH NIH HHS R01 MH064023NIMH NIH HHS R01 MH078113PHS HHS 60902PHS HHS 78113
6 · The paper itself

Abstract

The current construct of schizophrenia as a unitary disease is far from satisfactory, and is in need of reconceptualization. The first five papers in our "facts" series reviewed what is known about schizophrenia to date, and a limited number of key facts appear to stand out. Schizophrenia is characterized by persistent cognitive deficits, positive and negative symptoms typically beginning in youth, substantive heritability, and brain structural, functional and neurochemical alterations including dopaminergic dysregulation. Several pathophysiological models have been proposed with differing interpretations of the illness, like the fabled six blind Indian men groping different parts of an elephant coming up with different conclusions. However, accumulating knowledge is integrating the several extant models of schizophrenia etiopathogenesis into unifying constructs; we discuss an example, involving a neurodevelopmental imbalance in excitatory/inhibitory neural systems leading to impaired neural plasticity. This imbalance, which may be proximal to clinical manifestations, could result from a variety of genetic, epigenetic and environmental causes, as well as pathophysiological processes such as inflammation and oxidative stress. Such efforts to "connect the dots" (and visualizing the elephant) are still limited by the substantial clinical, pathological, and etiological heterogeneity of schizophrenia and its blurred boundaries with several other psychiatric disorders leading to a "fuzzy cluster" of overlapping syndromes, thereby reducing the content, discriminant and predictive validity of a unitary construct of this illness. The way ahead involves several key directions: a) choosing valid phenotype definitions increasingly derived from translational neuroscience; b) addressing clinical heterogeneity by a cross-diagnostic dimensional and a staging approach to psychopathology; c) addressing pathophysiological heterogeneity by elucidating independent families of "extended" intermediate phenotypes and pathophysiological processes (e.g. altered excitatory/inhibitory, salience or executive circuitries, oxidative stress systems) that traverse structural, functional, neurochemical and molecular domains; d) resolving etiologic heterogeneity by mapping genomic and environmental factors and their interactions to syndromal and specific pathophysiological signatures; e) separating causal factors from consequences and compensatory phenomena; and f) formulating or reformulating hypotheses that can be refuted/tested, perhaps in the mouse or other experimental models. These steps will likely lead to the current entity of schizophrenia being usefully deconstructed and reconfigured into phenotypically overlapping, but etiopathologically unique and empirically testable component entities (similar to mental retardation, epilepsy or cancer syndromes). The mouse may be the way to rescue the trapped elephant!

Indexed as

Disease Models, AnimalSchizophreniaAnimalsElephantsHumansMice

Identifiers

PMID21316923
PMCPMC3391657

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.